Key points from article :
Bionaut Labs is raising the curtain on its tiny, remote-controlled devices.
Smaller than a millimeter and with a few moving parts.
Guided only by magnetic fields generated outside the body.
To overcome the obvious constraint that holds back surgical drills, probes and needles.
To start, the company aims to tackle gliomas of the brainstem.
Safely navigate to the cancer and unlock a mechanism that delivers chemotherapies directly.
“Higher drug concentrations in situ, much lower to nonexistent concentrations in the plasma," - Michael Shpigelmacher, CEO of Bionaut Labs.
Preclinical studies on small and large live animals, showing no long-term neurological damage.
Raised $20 million to help take it to the next step and moving into human clinical trials planned for 2023.
“Therapeutic potential extends to many diseases where conventional therapies are limited or lacking," - Vinod Khosla, founder of Khosla Ventures.
